Irina V. Gubonina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Irina V. Gubonina has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
- Vladimir B. Grinevich
Kirov Military Medical Academy
8 shared publications - Diana I. Abdulganieva
Kazan State Medical University, Ministry of Health of Russia
6 shared publications - Elena A. Belousova
Moscow Regional Research and Clinical Institute (MONIKI)
5 shared publications - Oksana B. Shchukina
Pavlov First Saint Petersburg State Medical University
5 shared publications - Oleg V. Knyazev
Moscow Clinical Scientific Center named after Loginov
5 shared publications - Elena A. Poluektova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications
Latest Publications
- Open Access
- 23 April 2026
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 53 (6) , 306-314
Safety of 5-aminosalicylic acid therapy in the preconception period and during pregnancy in patients with ulcerative colitis: a multi-center, retrospective, registry-based observational study
Background: 5-Aminosalicylates (5-ASA) are first-line therapy for patients with ulcerative colitis (UC). Although the 2022 ECCO Consensus considers 5-ASA to be low-risk, data on their use during pregnancy remain conflicting. Aim: To investigate the course and outcomes of pregnancy in women with UC, as well as the disease activity during gestation, according to adherence to prescribed 5-ASA therapy. Methods: Data from the registries of seven inflammatory bowel disease centers in Russia were analyzed. The analysis included women with UC (International Classification of Diseases, 10th edition code K51) who received 5-ASA therapy alone and for whom medical records contained information on pregnancy course and outcome. Disease and pregnancy courses were compared between two groups: those adherent and those non adherent to prescribed 5-ASA therapy. Adherence was defined as starting 5-ASA at least 3 months before conception and continuing a stable dose admission throughout pregnancy; non adherence was defined as self-discontinuation of therapy upon becoming pregnant. Results: The study included 73 women with UC (48 aged 30 years, 25 aged 30–40 years). Of these, 58.9% received oral 5-ASA only (41 women mesalamine, 2 sulfasalazine), and 41.1% (n = 30) received combination therapy with rectal 5-ASA. In 8.2% (n = 6) of cases, patients switched from oral to combination therapy during pregnancy. The majority (82.2%, n = 60) continued prescribed 5-ASA therapy throughout pregnancy, while 17.8% (n = 13) discontinued it on their own upon becoming pregnant. The overall rate of UC relapse during pregnancy was 39.7% (29/73). UC recurrence was more frequent in the discontinuation group than in the fully adherent group: 92.3% (12/13) and 28.3% (17/60) respectively (p 0.001). Threatened miscarriage was also higher in the discontinuation group: 38.5% (5/13) and 13.3% (8/60) (p = 0.047) respectively. The composite rate of pregnancy complications (threatened miscarriage, preterm birth, early pregnancy termination) was 76.9% (10/13; 95% confidence interval [CI] 49.7–91.8) in non adherent patients vs. 21.7% (13/60; 95% CI 13.1–33.6) in adherent patients (p 0.001). Newborns in the maintenance 5-ASA therapy group more frequently had normal birth weight and Apgar scores (90.5%, n = 48) compared to those born to mothers who discontinued 5-ASA (42.8%, n = 3) (p = 0.007). No adverse events in women or congenital malformations in newborns were registered during 5-ASA treatment before conception and throughout pregnancy. Conclusion: Adherence to maintenance 5-ASA therapy in women with UC is associated with a more favorable pregnancy course and outcomes compared to discontinuation of therapy upon conception.
- 23 April 2026
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 53 (6) , 306-314
Open AccessSafety of 5-aminosalicylic acid therapy in the preconception period and during pregnancy in patients with ulcerative colitis: a multi-center, retrospective, registry-based observational study
Background: 5-Aminosalicylates (5-ASA) are first-line therapy for patients with ulcerative colitis (UC). Although the 2022 ECCO Consensus considers 5-ASA to be low-risk, data on their use during pregnancy remain conflicting. Aim: To investigate the course and outcomes of pregnancy in women with UC, as well as the disease activity during gestation, according to adherence to prescribed 5-ASA therapy. Methods: Data from the registries of seven inflammatory bowel disease centers in Russia were analyzed. The analysis included women with UC (International Classification of Diseases, 10th edition code K51) who received 5-ASA therapy alone and for whom medical records contained information on pregnancy course and outcome. Disease and pregnancy courses were compared between two groups: those adherent and those non adherent to prescribed 5-ASA therapy. Adherence was defined as starting 5-ASA at least 3 months before conception and continuing a stable dose admission throughout pregnancy; non adherence was defined as self-discontinuation of therapy upon becoming pregnant. Results: The study included 73 women with UC (48 aged 30 years, 25 aged 30–40 years). Of these, 58.9% received oral 5-ASA only (41 women mesalamine, 2 sulfasalazine), and 41.1% (n = 30) received combination therapy with rectal 5-ASA. In 8.2% (n = 6) of cases, patients switched from oral to combination therapy during pregnancy. The majority (82.2%, n = 60) continued prescribed 5-ASA therapy throughout pregnancy, while 17.8% (n = 13) discontinued it on their own upon becoming pregnant. The overall rate of UC relapse during pregnancy was 39.7% (29/73). UC recurrence was more frequent in the discontinuation group than in the fully adherent group: 92.3% (12/13) and 28.3% (17/60) respectively (p 0.001). Threatened miscarriage was also higher in the discontinuation group: 38.5% (5/13) and 13.3% (8/60) (p = 0.047) respectively. The composite rate of pregnancy complications (threatened miscarriage, preterm birth, early pregnancy termination) was 76.9% (10/13; 95% confidence interval [CI] 49.7–91.8) in non adherent patients vs. 21.7% (13/60; 95% CI 13.1–33.6) in adherent patients (p 0.001). Newborns in the maintenance 5-ASA therapy group more frequently had normal birth weight and Apgar scores (90.5%, n = 48) compared to those born to mothers who discontinued 5-ASA (42.8%, n = 3) (p = 0.007). No adverse events in women or congenital malformations in newborns were registered during 5-ASA treatment before conception and throughout pregnancy. Conclusion: Adherence to maintenance 5-ASA therapy in women with UC is associated with a more favorable pregnancy course and outcomes compared to discontinuation of therapy upon conception.
- Open Access
- 7 October 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (4) , 88-97
Results of a Multicenter Prospective Observational Study “ALLIANCE” on the Impact of Rifaximin and Trimebutine on Quality of Life and the Course of Uncomplicated Diverticular Disease in Outpatient Clinical Practice
Aim: to evaluate the impact of the drugs Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) on symptom severity and quality of life in patients with uncomplicated diverticular disease.Materials and methods. A multicenter non-interventional prospective observational study was conducted, involving 100 patients diagnosed with uncomplicated diverticular disease. Patients received Alfaxim® (rifaximin) at 400 mg 2–3 times daily for 7 days monthly over 6 months and Neobutin Retard® (trimebutine) at 300 mg twice daily for 4 weeks, in addition to standard therapy. Symptom severity (abdominal pain, constipation, diarrhea, bloating, tenesmus) was assessed using a 3-point scale. Quality of life was evaluated using the SF-12 questionnaire. Patient adherence to treatment was measured using the Morisky — Green Compliance Scale.Results. Cyclic therapy with Alfaxim® and Neobutin Retard® showed statistically significant (p < 0.001) positive effects on all assessed symptoms. Over half of the patients (55 %) achieved remission by the end of the observation period. Analysis of SF-12 scores revealed a significant improvement in quality of life (p < 0.001). Most patients demonstrated high treatment adherence throughout the study. No adverse events were recorded during the observation period.Conclusions. The use of Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) reduces symptom severity and improves quality of life in patients with uncomplicated diverticular disease. The drugs have a favorable safety profile.
- 7 October 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (4) , 88-97
Open AccessResults of a Multicenter Prospective Observational Study “ALLIANCE” on the Impact of Rifaximin and Trimebutine on Quality of Life and the Course of Uncomplicated Diverticular Disease in Outpatient Clinical Practice
Aim: to evaluate the impact of the drugs Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) on symptom severity and quality of life in patients with uncomplicated diverticular disease.Materials and methods. A multicenter non-interventional prospective observational study was conducted, involving 100 patients diagnosed with uncomplicated diverticular disease. Patients received Alfaxim® (rifaximin) at 400 mg 2–3 times daily for 7 days monthly over 6 months and Neobutin Retard® (trimebutine) at 300 mg twice daily for 4 weeks, in addition to standard therapy. Symptom severity (abdominal pain, constipation, diarrhea, bloating, tenesmus) was assessed using a 3-point scale. Quality of life was evaluated using the SF-12 questionnaire. Patient adherence to treatment was measured using the Morisky — Green Compliance Scale.Results. Cyclic therapy with Alfaxim® and Neobutin Retard® showed statistically significant (p < 0.001) positive effects on all assessed symptoms. Over half of the patients (55 %) achieved remission by the end of the observation period. Analysis of SF-12 scores revealed a significant improvement in quality of life (p < 0.001). Most patients demonstrated high treatment adherence throughout the study. No adverse events were recorded during the observation period.Conclusions. The use of Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) reduces symptom severity and improves quality of life in patients with uncomplicated diverticular disease. The drugs have a favorable safety profile.
- Open Access
- 26 March 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (2) , 198-213
Russian Cross-disciplinary Consensus on the diagnosis and treatment of spondyloarthritis associated with inflammatory bowel diseases
The Russian Cross-disciplinary Consensus on the diagnositic and treatment of spondyloarthritis (SpA) in inflammatory bowel diseases (IBD) was prepared on the initiative of the Loginov Moscow Clinical Scientific Center, using the Delphic system. Its purpose was to consolidate the opinions of experts on the most actual issues of diagnosis and treatment of concomitant immuno-inflammatory diseases (SpA and IBD). An interdisciplinary approach is provided by the participation of leading gastroenterologists and rheumatologists. The working group analyzed domestic and foreign publications on the problem of curation of patients with SpA and IBD. There have been 17 statements and 2 treatment algorithms formulated. Statements 1–3 reflect the fundamental principles of management of patients with SpA and IBD. The principles of early diagnosis of SpA and IBD, including the diagnosis of complications of therapy, are described below. Eleven statements are devoted to current methods of treatment, on the basis of which 2 treatment algorithms have been developed. The statements of the Consensus were submitted to the Expert Council for consideration, edits were made, after which an online vote took place. This paper presents current recommendations for the management, diagnosis and treatment of patients with SpA and IBD.
- 26 March 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (2) , 198-213
Open AccessRussian Cross-disciplinary Consensus on the diagnosis and treatment of spondyloarthritis associated with inflammatory bowel diseases
The Russian Cross-disciplinary Consensus on the diagnositic and treatment of spondyloarthritis (SpA) in inflammatory bowel diseases (IBD) was prepared on the initiative of the Loginov Moscow Clinical Scientific Center, using the Delphic system. Its purpose was to consolidate the opinions of experts on the most actual issues of diagnosis and treatment of concomitant immuno-inflammatory diseases (SpA and IBD). An interdisciplinary approach is provided by the participation of leading gastroenterologists and rheumatologists. The working group analyzed domestic and foreign publications on the problem of curation of patients with SpA and IBD. There have been 17 statements and 2 treatment algorithms formulated. Statements 1–3 reflect the fundamental principles of management of patients with SpA and IBD. The principles of early diagnosis of SpA and IBD, including the diagnosis of complications of therapy, are described below. Eleven statements are devoted to current methods of treatment, on the basis of which 2 treatment algorithms have been developed. The statements of the Consensus were submitted to the Expert Council for consideration, edits were made, after which an online vote took place. This paper presents current recommendations for the management, diagnosis and treatment of patients with SpA and IBD.
- 24 March 2025
- Published by Alfmed LLC in Medical alphabet
- No. 5,p. 26-33
Diagnostic and prognostic significance of pancreatic autoantibodies and intestinal goblet cell antibodies in inflammatory bowel diseases
Background: serological profiling of inflammatory bowel diseases (IBD) using autoantibodies represents an additional non-invasive tool for differential diagnosis and prognosis of the clinical course of Crohn’s disease (CD) and ulcerative colitis (UC).Aim: to determine the frequency, diagnostic and prognostic significance of pancreatic autoantibodies (PAB), autoantibodies to glycoprotein 2 (GP2) and intestinal goblet cells antibodies (GAB) in assessing the clinical outcomes of CD and UC.Materials and methods: the study included 117 patients with CD, 45 with UC and 24 with IBD unclassified (IBDU). The comparison group consisted of 36 patients with other gastrointestinal diseases (irritable bowel syndrome with diarrhea (IBS-D), celiac disease, autoimmune gastritis (AIH)), the control group consisted of 29 conditionally healthy individuals. The content of PAB and GAB class IgG was measured by the IIF method (EUROIMMUN AG, Germany), GP2 classes IgA and IgG and fecal calprotectin (FCP) – by the ELISA method (Generic Assays GmbH, Germany, BÜHLMANN Laboratories AG, Switzerland).Results: the frequency of PAB IgG, GP2 IgA and GP2 IgG in patients with CD was 25.6%, 24% and 12%, respectively, which was significantly higher compared to patients with UC (6.6%, 15.5% and 4.4%), IBDU (4.1%, 12.5% and 0%), AIH (5.2%, 0% and 5.2%), IBS-D (0%, 0% and 0%) and the control group (6.9%, 3.4% and 6.9%) (pConclusion: serological examination of IBD with combined determination of PAB IgG, GP2 IgA, GP2 IgG and GAB IgG allows to increase the efficiency of differential diagnostics and prediction of individual course of CD and UC.
- 24 March 2025
- Published by Alfmed LLC in Medical alphabet
- No. 5,p. 26-33
Diagnostic and prognostic significance of pancreatic autoantibodies and intestinal goblet cell antibodies in inflammatory bowel diseases
Background: serological profiling of inflammatory bowel diseases (IBD) using autoantibodies represents an additional non-invasive tool for differential diagnosis and prognosis of the clinical course of Crohn’s disease (CD) and ulcerative colitis (UC).Aim: to determine the frequency, diagnostic and prognostic significance of pancreatic autoantibodies (PAB), autoantibodies to glycoprotein 2 (GP2) and intestinal goblet cells antibodies (GAB) in assessing the clinical outcomes of CD and UC.Materials and methods: the study included 117 patients with CD, 45 with UC and 24 with IBD unclassified (IBDU). The comparison group consisted of 36 patients with other gastrointestinal diseases (irritable bowel syndrome with diarrhea (IBS-D), celiac disease, autoimmune gastritis (AIH)), the control group consisted of 29 conditionally healthy individuals. The content of PAB and GAB class IgG was measured by the IIF method (EUROIMMUN AG, Germany), GP2 classes IgA and IgG and fecal calprotectin (FCP) – by the ELISA method (Generic Assays GmbH, Germany, BÜHLMANN Laboratories AG, Switzerland).Results: the frequency of PAB IgG, GP2 IgA and GP2 IgG in patients with CD was 25.6%, 24% and 12%, respectively, which was significantly higher compared to patients with UC (6.6%, 15.5% and 4.4%), IBDU (4.1%, 12.5% and 0%), AIH (5.2%, 0% and 5.2%), IBS-D (0%, 0% and 0%) and the control group (6.9%, 3.4% and 6.9%) (pConclusion: serological examination of IBD with combined determination of PAB IgG, GP2 IgA, GP2 IgG and GAB IgG allows to increase the efficiency of differential diagnostics and prediction of individual course of CD and UC.
- 4 April 2024
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 13 (1)
Bile acid malabsorption in inflammatory bowel diseases
Bile acid malabsorption (BAM), clinically manifesting as hologenic diarrhea, is one of the common but often overlooked symptoms of inflammatory bowel diseases (IBD). OBJECTIVE To assess the level of fecal excretion of BA in patients with IBD and the possibility of using the determination of BA in feces in the diagnosis of diarrhea and the clinical course of Crohn’s disease (CD) and ulcerative colitis (UC). MATERIAL AND METHODS The study included 62 stool samples from clinically examined patients with CD, 26 — with UC, 20 — with IBD unclassified (IBDU), and 15 stool samples from healthy individuals, in which concentrations of fecal BA, fecal calprotectin (FC) and stool osmotic gap (SOG) were measured. The associations of these markers with diarrhea, localization, severity, disease phenotype, and surgical treatment of IBD were determined. RESULTS The mean concentration of fecal BA was significantly higher in patients with CD (113.3±303.1 µmol/g), UC (41.72±112.5 µmol/g) and IBDU (44.41±99, 6 µmol/g) compared with the control group (0.9±1.35 µmol/g) (ppr= –0.48, p=0.002). In 51.2% of patients with IBD with diarrhea and low values of SOG, high concentrations of fecal BA (134.7±321.8 µmol/g) and FC (1035±774.4 µg/g) were combined (r=0.29, p=0.03). The level of faecal excretion of fatty acids was significantly higher in patients with terminal ileitis (226±566.5 µmol/g) and stenosing CD phenotype (150±479.8 µmol/g) compared with patients with colitis, ileocolitis and involvement of the upper gastrointestinal tract and luminal CD phenotype, respectively. In CD patients with ileocecal resection, the frequency of detection and the mean concentration of fecal BA were higher compared with patients without removal of the terminal ileum — 85.7% (127.7±116.4 µmol/g) vs. 18.1% (21.82±53.13 µmol/g), respectively (p=0.01). CONCLUSIONS Determination of the concentration of fecal BA allows diagnosing type BAM, as well as identifying subgroups of patients with chologenoic and chologeno-inflammatory types of diarrheal syndrome in IBD. Clinically significant BAM is associated with terminal ileitis, a stricture phenotype, and ileocecal resection in CD. Assessment of faecal FA excretion can serve as a potential therapeutic target for the development of new treatments for IBD.
- 4 April 2024
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 13 (1)
Bile acid malabsorption in inflammatory bowel diseases
Bile acid malabsorption (BAM), clinically manifesting as hologenic diarrhea, is one of the common but often overlooked symptoms of inflammatory bowel diseases (IBD). OBJECTIVE To assess the level of fecal excretion of BA in patients with IBD and the possibility of using the determination of BA in feces in the diagnosis of diarrhea and the clinical course of Crohn’s disease (CD) and ulcerative colitis (UC). MATERIAL AND METHODS The study included 62 stool samples from clinically examined patients with CD, 26 — with UC, 20 — with IBD unclassified (IBDU), and 15 stool samples from healthy individuals, in which concentrations of fecal BA, fecal calprotectin (FC) and stool osmotic gap (SOG) were measured. The associations of these markers with diarrhea, localization, severity, disease phenotype, and surgical treatment of IBD were determined. RESULTS The mean concentration of fecal BA was significantly higher in patients with CD (113.3±303.1 µmol/g), UC (41.72±112.5 µmol/g) and IBDU (44.41±99, 6 µmol/g) compared with the control group (0.9±1.35 µmol/g) (ppr= –0.48, p=0.002). In 51.2% of patients with IBD with diarrhea and low values of SOG, high concentrations of fecal BA (134.7±321.8 µmol/g) and FC (1035±774.4 µg/g) were combined (r=0.29, p=0.03). The level of faecal excretion of fatty acids was significantly higher in patients with terminal ileitis (226±566.5 µmol/g) and stenosing CD phenotype (150±479.8 µmol/g) compared with patients with colitis, ileocolitis and involvement of the upper gastrointestinal tract and luminal CD phenotype, respectively. In CD patients with ileocecal resection, the frequency of detection and the mean concentration of fecal BA were higher compared with patients without removal of the terminal ileum — 85.7% (127.7±116.4 µmol/g) vs. 18.1% (21.82±53.13 µmol/g), respectively (p=0.01). CONCLUSIONS Determination of the concentration of fecal BA allows diagnosing type BAM, as well as identifying subgroups of patients with chologenoic and chologeno-inflammatory types of diarrheal syndrome in IBD. Clinically significant BAM is associated with terminal ileitis, a stricture phenotype, and ileocecal resection in CD. Assessment of faecal FA excretion can serve as a potential therapeutic target for the development of new treatments for IBD.
- Open Access
- 9 February 2024
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 31 (1) , 37-46
Predictive value of ASCA and ANCA in inflammatory bowel diseases
Introduction. Serological diagnosis of inflammatory bowel diseases (IBD) is an additional tool not only for differential diagnosis, but also for individual prediction of the clinical course and long-term outcomes of Crohn’s disease (CD) and ulcerative colitis (UC).The objective was to assess the occurrence and capabilities of determining antibodies to Saccharomyces cerevisiae (ASCA) and antineutrophil cytoplasmic antibodies (ANCA) in predicting the clinical outcomes of IBD.Methods and materials. The study included 71 patients with CD, 26 with UC, and 21 with and 21 with IBD unclassified (IBDU). The comparison group consisted of 35 patients with other gastrointestinal diseases (irritable bowel syndrome with diarrhea (IBS-D), celiac disease, autoimmune gastritis (AIG)); the control group consisted of 24 apparently healthy individuals. The level of antibodies to ASCA IgA and IgG was measured by the ELISA method (ORGENTEC Diagnostika GmbH, Germany), ANCA IgG was determined by the IIF method of the Granulocyte Mosaic test system (EUROIMMUN AG, Germany).Results. The occurrence of ASCA IgA and IgG in patients with CD was 25 % and 38 %, which is significantly higher compared to patients with UC (0 % and 3.8 %), IBDU (5 % and 5 %), AIG (0 % and 5.3 %) respectively (pConclusion. ASCA and ANCA are highly specific markers of CD and UC, the combined determination of which makes it possible to increase the efficiency of serological examination not only in differential diagnosis, but also in personalized prediction of the clinical course of IBD.
- 9 February 2024
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 31 (1) , 37-46
Open AccessPredictive value of ASCA and ANCA in inflammatory bowel diseases
Introduction. Serological diagnosis of inflammatory bowel diseases (IBD) is an additional tool not only for differential diagnosis, but also for individual prediction of the clinical course and long-term outcomes of Crohn’s disease (CD) and ulcerative colitis (UC).The objective was to assess the occurrence and capabilities of determining antibodies to Saccharomyces cerevisiae (ASCA) and antineutrophil cytoplasmic antibodies (ANCA) in predicting the clinical outcomes of IBD.Methods and materials. The study included 71 patients with CD, 26 with UC, and 21 with and 21 with IBD unclassified (IBDU). The comparison group consisted of 35 patients with other gastrointestinal diseases (irritable bowel syndrome with diarrhea (IBS-D), celiac disease, autoimmune gastritis (AIG)); the control group consisted of 24 apparently healthy individuals. The level of antibodies to ASCA IgA and IgG was measured by the ELISA method (ORGENTEC Diagnostika GmbH, Germany), ANCA IgG was determined by the IIF method of the Granulocyte Mosaic test system (EUROIMMUN AG, Germany).Results. The occurrence of ASCA IgA and IgG in patients with CD was 25 % and 38 %, which is significantly higher compared to patients with UC (0 % and 3.8 %), IBDU (5 % and 5 %), AIG (0 % and 5.3 %) respectively (pConclusion. ASCA and ANCA are highly specific markers of CD and UC, the combined determination of which makes it possible to increase the efficiency of serological examination not only in differential diagnosis, but also in personalized prediction of the clinical course of IBD.
- Open Access
- 6 October 2023
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 51 (4) , 253-258
A clinical case of pyoderma gangrenosum as a severe extraintestinal manifestation of Crohn’s disease
Pyoderma gangrenosum is a rare neutrophilic dermatosis associated with a number of immune-mediated disorders, most frequently with inflammatory bowel disease and rheumatoid arthritis. Despite significant success in the treatment in inflammatory bowel disease, the problem of multidisciplinary management of patients with extraintestinal manifestations in routine medical practice remains unsolved. The paper presents a clinical case of a 32-year old female patient with a life-threatening extraintestinal manifestation of Crohn's disease, i. e. pyoderma gangrenosum. Late diagnosis of Crohn's disease, underestimation of the inflammation activity in the gut and respective lack of disease-modifying treatment were the reasons for the occurrence of pyoderma gangrenosum and its uncontrolled course. The untimely diagnosis of the skin purulent wound as an extraintestinal manifestation of Crohn's disease has led to delay in the immunosuppressive therapy required. The patient needed an intensive course of systemic glucocorticosteroids, prompt addition of a tumor necrosis factor-alpha inhibitor and surgery as a circulatory autodermoplasty.
- 6 October 2023
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 51 (4) , 253-258
Open AccessA clinical case of pyoderma gangrenosum as a severe extraintestinal manifestation of Crohn’s disease
Pyoderma gangrenosum is a rare neutrophilic dermatosis associated with a number of immune-mediated disorders, most frequently with inflammatory bowel disease and rheumatoid arthritis. Despite significant success in the treatment in inflammatory bowel disease, the problem of multidisciplinary management of patients with extraintestinal manifestations in routine medical practice remains unsolved. The paper presents a clinical case of a 32-year old female patient with a life-threatening extraintestinal manifestation of Crohn's disease, i. e. pyoderma gangrenosum. Late diagnosis of Crohn's disease, underestimation of the inflammation activity in the gut and respective lack of disease-modifying treatment were the reasons for the occurrence of pyoderma gangrenosum and its uncontrolled course. The untimely diagnosis of the skin purulent wound as an extraintestinal manifestation of Crohn's disease has led to delay in the immunosuppressive therapy required. The patient needed an intensive course of systemic glucocorticosteroids, prompt addition of a tumor necrosis factor-alpha inhibitor and surgery as a circulatory autodermoplasty.
- Open Access
- 5 June 2023
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 22 (2) , 172-183
Consensus on controversial issues of the surgery for Crohn’s disease by Delphi method
AIM: to establish the consensus on controversial issues of the surgery for Сrohn’s disease by Delphi method.METHODS: a cross-sectional study was conducted by the Delphi method. 62 experts voted intramural and anonymous (31.03.23). 5 statements from the current edition of clinical guidelines were selected for correction by working group and further voting [2]. Based on the practical experience of the working group and literature data, 3 new statements were created also. Statements that do not reach the required level of agreement (80% or more) will be subjected to Round 2 of the Delphi method.RESULTS: all experts took part in the anonymous voting. The panel of experts is represented by 8 different areas of practical medicine and the median of the professional experience of the respondents was 30 (12–49) years. Of the 8 statements submitted for voting, consensus (80% or more) was reached on 6 out of 8. 2 statements have been revised by working group for the distance 2nd round of the Delphi study. Consensus (more than 80%) was reached on both.CONCLUSION: a cross-sectional study by the Delphi method provided the opinions of a panel of experts on controversial issues in the surgical treatment of Crohn’s disease. Statements that reach consensus will be included by the working group in a new edition of clinical guidelines of Crohn’s disease.
- 5 June 2023
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 22 (2) , 172-183
Open AccessConsensus on controversial issues of the surgery for Crohn’s disease by Delphi method
AIM: to establish the consensus on controversial issues of the surgery for Сrohn’s disease by Delphi method.METHODS: a cross-sectional study was conducted by the Delphi method. 62 experts voted intramural and anonymous (31.03.23). 5 statements from the current edition of clinical guidelines were selected for correction by working group and further voting [2]. Based on the practical experience of the working group and literature data, 3 new statements were created also. Statements that do not reach the required level of agreement (80% or more) will be subjected to Round 2 of the Delphi method.RESULTS: all experts took part in the anonymous voting. The panel of experts is represented by 8 different areas of practical medicine and the median of the professional experience of the respondents was 30 (12–49) years. Of the 8 statements submitted for voting, consensus (80% or more) was reached on 6 out of 8. 2 statements have been revised by working group for the distance 2nd round of the Delphi study. Consensus (more than 80%) was reached on both.CONCLUSION: a cross-sectional study by the Delphi method provided the opinions of a panel of experts on controversial issues in the surgical treatment of Crohn’s disease. Statements that reach consensus will be included by the working group in a new edition of clinical guidelines of Crohn’s disease.
- Open Access
- 10 May 2023
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 51 (1) , 1-13
Bile acid dysmetabolism in inflammatory bowel diseases
Aim: To summarize the state-of-the-art data on the molecular mechanisms of bile acid (BA) synthesis and absorption, their impaired absorption and receptor-dependent signaling, as well as on the effects of the gut microbiota on BA metabolism in inflammatory bowel diseases (IBD). Key messages: BA malabsorption is one of the relevant mechanisms in the development of diarrhea in IBD. It may occur due to various disorders of the ileum, such as terminal ileitis, ileocolitis or ileocecal resection in Crohn's disease and ileoanal reservoir in ulcerative colitis. Molecular mechanisms of BA malabsorption in IBD are related to a defect in the BA uptake by the apical sodium dependent bile acid transporter (ASBT), as well as to a decrease in the expression of pregnane X receptor (PXR) and farnesoid X receptor (FXR), whose activation by glucocorticoids results in an increase in the BA reabsorption in the ileum and a decrease in hologenic diarrhea. The metabolic profile of luminal BA in IBD is characterized by an increased content of conjugated and 3-OH-sulfated BA and reduced levels of secondary BA. The decrease in the relative abundance of the Lachnospiraceae and Oscillospiraceae spp. in IBD patients leads to a decrease in the efficiency of microbial biotransformation of BA. Changes in the BA metabolic profile in IBD affect the gut microbiota, and impaired interaction with the FXR, PXR, G protein-coupled bile acid receptor (GPBAR1), retinoid-related orphan receptors (RORs) and vitamin D receptor (VDR) results in a pro-inflammatory response and increased intestinal permeability, bacterial translocation, and IBD progression. BA metabolism in IBD-associated primary sclerosing cholangitis (PSC-IBD) is characterized by a significant decrease in the luminal BA pool, and the microbiota composition is remarkable for an increase in the relative abundance of Fusobacterium and Ruminococcus spp., and a decrease in Veillonella, Dorea, Blautia, Lachnospira and Roseburia. Conclusion: Disordered synergistic interplay of BA with intestinal microbiota results in disruption of the ligand-receptor interaction and BA metabolic transformation, which contributes to the activation of the immune system, formation of a vicious circle of chronic inflammation and IBD progression. Further studies into mutual influence of the gut microbiota, BA metabolism and receptor signaling may promote the development of new methods for the diagnosis and treatment of IBD.
- 10 May 2023
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 51 (1) , 1-13
Open AccessBile acid dysmetabolism in inflammatory bowel diseases
Aim: To summarize the state-of-the-art data on the molecular mechanisms of bile acid (BA) synthesis and absorption, their impaired absorption and receptor-dependent signaling, as well as on the effects of the gut microbiota on BA metabolism in inflammatory bowel diseases (IBD). Key messages: BA malabsorption is one of the relevant mechanisms in the development of diarrhea in IBD. It may occur due to various disorders of the ileum, such as terminal ileitis, ileocolitis or ileocecal resection in Crohn's disease and ileoanal reservoir in ulcerative colitis. Molecular mechanisms of BA malabsorption in IBD are related to a defect in the BA uptake by the apical sodium dependent bile acid transporter (ASBT), as well as to a decrease in the expression of pregnane X receptor (PXR) and farnesoid X receptor (FXR), whose activation by glucocorticoids results in an increase in the BA reabsorption in the ileum and a decrease in hologenic diarrhea. The metabolic profile of luminal BA in IBD is characterized by an increased content of conjugated and 3-OH-sulfated BA and reduced levels of secondary BA. The decrease in the relative abundance of the Lachnospiraceae and Oscillospiraceae spp. in IBD patients leads to a decrease in the efficiency of microbial biotransformation of BA. Changes in the BA metabolic profile in IBD affect the gut microbiota, and impaired interaction with the FXR, PXR, G protein-coupled bile acid receptor (GPBAR1), retinoid-related orphan receptors (RORs) and vitamin D receptor (VDR) results in a pro-inflammatory response and increased intestinal permeability, bacterial translocation, and IBD progression. BA metabolism in IBD-associated primary sclerosing cholangitis (PSC-IBD) is characterized by a significant decrease in the luminal BA pool, and the microbiota composition is remarkable for an increase in the relative abundance of Fusobacterium and Ruminococcus spp., and a decrease in Veillonella, Dorea, Blautia, Lachnospira and Roseburia. Conclusion: Disordered synergistic interplay of BA with intestinal microbiota results in disruption of the ligand-receptor interaction and BA metabolic transformation, which contributes to the activation of the immune system, formation of a vicious circle of chronic inflammation and IBD progression. Further studies into mutual influence of the gut microbiota, BA metabolism and receptor signaling may promote the development of new methods for the diagnosis and treatment of IBD.
- Open Access
- 5 March 2023
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 22 (1) , 65-82
Clinical and Demographic Features and Treatment Approaches for Inflammatory Bowel Diseases (Crohn’s Disease, Ulcerative Colitis) in the Russia. The Primery Results of the Analysis of the National Register
The National Registry of Patients with Inflammatory Bowel Disease (IBD) in the Russian Federation was established to study the epidemiological and clinical characteristics of patients and evaluate the actual clinical practice of medical and surgical treatment.AIM: to analyze the data of patients with IBD in the Russian Federation including clinical and demographic characteristics, medical status of patients, the frequency of use of various classes of drugs and response to treatment, the survival rates of advanced therapy drugs and the reasons for their cancellation.METHODS: from May 2017 to August 2021, depersonalized data of 3827 adult patients with IBD (ulcerative colitis (UC) – 2358 pts, Crohn's disease (CD) - 1469 pts) from 80 regions of the Russian Federation were included in the registry, both with previously and newly diagnosed UCor CD, who are in inpatient or outpatient care.RESULTS: in our population, the ratio of UC: CD was 1.6:1. The distribution of patients by sex was the same. The average age of patients in the registry was 40.6±13.1 (13-83 years) for UC and 38.5±14.3 (15-75 years) for CD, the half of patients were in the age range of 21-40 years for both diseases. The average age of disease onset did not differ for UC and CD and was 35.3 year (12-75 years) and 31.2 year (14-72 years) respectively. The duration between the onset of symptoms and the establishment of a diagnosis was 13.2 months in UC, and statistically significantly longer in CD - 34.8 months (PCONCLUSION: The difficulties of differential, often untimely diagnosis of CD and UC, the predominance of complicated and severe forms against the background of an increase in morbidity and prevalence, and at the same time the lack of adequate statistical accounting of CD and UC, make it necessary to create a unified clinical register of patients with IBD. The register of IBD patients will provide a holistic picture of the IBD situation in the country, including optimizing the use of budget funds for the treatment of patients with CD and UC, ensuring their rational planning.
- 5 March 2023
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 22 (1) , 65-82
Open AccessClinical and Demographic Features and Treatment Approaches for Inflammatory Bowel Diseases (Crohn’s Disease, Ulcerative Colitis) in the Russia. The Primery Results of the Analysis of the National Register
The National Registry of Patients with Inflammatory Bowel Disease (IBD) in the Russian Federation was established to study the epidemiological and clinical characteristics of patients and evaluate the actual clinical practice of medical and surgical treatment.AIM: to analyze the data of patients with IBD in the Russian Federation including clinical and demographic characteristics, medical status of patients, the frequency of use of various classes of drugs and response to treatment, the survival rates of advanced therapy drugs and the reasons for their cancellation.METHODS: from May 2017 to August 2021, depersonalized data of 3827 adult patients with IBD (ulcerative colitis (UC) – 2358 pts, Crohn's disease (CD) - 1469 pts) from 80 regions of the Russian Federation were included in the registry, both with previously and newly diagnosed UCor CD, who are in inpatient or outpatient care.RESULTS: in our population, the ratio of UC: CD was 1.6:1. The distribution of patients by sex was the same. The average age of patients in the registry was 40.6±13.1 (13-83 years) for UC and 38.5±14.3 (15-75 years) for CD, the half of patients were in the age range of 21-40 years for both diseases. The average age of disease onset did not differ for UC and CD and was 35.3 year (12-75 years) and 31.2 year (14-72 years) respectively. The duration between the onset of symptoms and the establishment of a diagnosis was 13.2 months in UC, and statistically significantly longer in CD - 34.8 months (PCONCLUSION: The difficulties of differential, often untimely diagnosis of CD and UC, the predominance of complicated and severe forms against the background of an increase in morbidity and prevalence, and at the same time the lack of adequate statistical accounting of CD and UC, make it necessary to create a unified clinical register of patients with IBD. The register of IBD patients will provide a holistic picture of the IBD situation in the country, including optimizing the use of budget funds for the treatment of patients with CD and UC, ensuring their rational planning.